



Odyssean Investment Trust PLC

Q3 2025 Quarterly Update

FOR PROFESSIONAL CLIENTS ONLY¹. NOT FOR FURTHER DISTRIBUTION.

¹ within the meaning of the Financial Conduct Authority COBS 3.5

Important Information



- The information contained in this document is for the use of **Professional and Institutional Investors only** and should not be relied upon by any other person
- This marketing communication does not include sufficient detail to enable the recipient to make an informed decision. Please refer to OIT prospectus, latest Annual Report and KID available at www.oitplc.com for more information about the investment policy, objective and risk profile of OIT
- Past performance is not a reliable indicator of future performance and investors may not get back the value of their original investment
- The value of Odyssean Investment Trust PLC (“OIT”) and the income derived from it may go down as well as up and is not guaranteed
- Investment in OIT may not be appropriate for investors who plan to withdraw their money within 5 years
- OIT’s portfolio is focused towards small and mid-sized companies; these may involve a higher degree of risk than larger sized companies. OIT does not attempt to match the composition of any index
- Shares of the Company may trade at a discount or premium to Net Asset Value for variety of reasons including market sentiment and market conditions. On a sale you could realise less than the Net Asset Value and less than you initially invested
- Case studies are selected for illustrative purposes only to illustrate the investment strategy and are not investment recommendations
- We draw readers’ attention to the ‘Important Information’ pages at the end of the presentation

Executive Summary – Q3 2025



NAV rises broadly in-line with market. Portfolio trading updates positive

- NAV per share rose 2.5%^{1,2} in the period. DNSC +AIM ex IC index (“Comparator”) rose 2.9% ^{2,3}
- Trading updates across the portfolio remain broadly positive
- Portfolio average EV/Sales ratings remain depressed – bottom quintile since June 2006
- Key portfolio news:
 - **NCC** – Alongside ongoing review of Escode division, announced reviewing strategic options for its Cyber division
 - **Elementis** – Strong H1 results with new CEO identifying ambitious new financial targets for margin and growth
 - **XP Power** – Interim book to bill >1.0x, record pipeline of new product launches and improving gross margin
 - **Dialight** – Strong trading update, delivering progress on profits despite ongoing market headwinds. Cash strong
 - **Genus** – Full year results strong, further £9m cost out identified and China opportunity de-risked through sale of JV stake for \$167m. On completion, net debt/EBITDA will fall <1x
 - **James Fisher** – in line half year trading update and interim results. Defence order book +45%
 - **Spire** – Announced strategic review to maximise/crystallise shareholder value
 - **Blackline** – Q3 results. YoY growth of 12%, but subscription sales up c.28%. Material new customer win with ADNOC
- OIT's shares ended the period trading at a 5.9% discount to NAV per share of 167.3p^{1,2} Net cash at 1.3%
- No OIT shares issued in the quarter. NAV at period end £224.1m. Blocklisting remains in situ



- **Dialight** – half year trading update with material upgrades despite challenging sales environment
- **G&H** – post year end trading update broadly in line
 - Significant growth in order book – currently £142m end Sept 2025, up from £105m Sept 2024 and £122m March 2025
 - Signs of recovery beginning in semiconductor related business
- **Xaar** – In line 9-month trading statement. Historic tax liability of c.£4m disclosed
- **XP Power** – notice of Q3 trading statement late October
 - First appearance at an investor conference for almost three years
 - Announced investor seminar for early November - first for several years

Performance update


NAV per share up 2.5% in Q3, broader market rose 2.9%



Performance

	%									Since inception	Annualised since inception
	Q3-25	CY25 YTD	CY24	CY23	CY22	CY21	CY20	CY19	Inception to Dec-18		
NAV Total Return Per Share ¹	+2.5%	+9.4%	-0.8%	-10.4%	+5.5%	+25.0%	+13.1%	+22.0%	-3.7%	70.2%	7.4%
Share price return ³	-2.2%	+2.3%	-2.5%	-9.3%	+5.0%	+28.7%	+14.2%	+17.7%	-4.0%	57.5%	6.3%
DNSC + AIM ex IC Total Return ³	+2.9%	+10.1%	+5.0%	+3.2%	-21.9%	+20.0%	+4.9%	+22.2%	-15.0%	22.1%	2.7%
Average cash balance ²	1%	1%	2%	2%	5%	8%	9%	17%	65%	12%	12%

Rebased NAV per share and share price vs comparator index¹



NAV per share performance vs comparator index¹



As at 30th September 2025. Performance measured from COB 1/5/18, share performance since inception assumes IPO price of 100p. Source: ¹Link Asset Services, Bloomberg, Odyssean Capital, Deutsche Numis Smaller Companies (“DNSC”) plus AIM ex Investment Companies Total Return Index (“Comparator”). Rebased to start NAV ² Link Asset Services, Odyssean Capital. ³ Bloomberg. DNSC + AIM ex Investment Company index is only used for the purposes of calculating performance fees. OIT does not attempt to match the composition of this index. The investment strategy is unconstrained and not benchmarked against any particular index. **Past performance is no guarantee of future performance** and the value of investments can go up and down.

Performance drivers in Q3 2025

Key stock contributors



Largest positive contributors

- Positive trading updates with self-help driving margins ahead of expectations, despite continued softness in end markets. Cash generation also ahead
- Increasing confidence in mid-term targets of returning group to 11%-13%, with improving topline progress as markets recover



- Strong full year results, volume growth in both divisions, cost out delivered ahead of expectation and further £9m identified
- Progress on key strategic initiatives: De-risked China opportunity through sale of JV stake - \$167m proceeds to de-gear group; Disease resistant pig approval continues to progress

- H1 results demonstrated strong order momentum in metrology division and full year guidance reiterated
- Well attended Capital Markets event saw group confirm mid-term targets of c.€500m revenue and 20%-25% EBITDA – materially above current levels

Largest negative contributors

- H1 results in-line, with strong demand in Aerospace and Defence (“A&D”) and life science. Orderbook gives good visibility on full year
- Bolt-on acquisition grows footprint in US and strengthens A&D capability
- Despite positive updates, shares drifted down following strong performance in prior quarter



- H1 results in-line, revenue growth 7% with 20% growth in printheads. Continued progress on launches in key new growth areas underpin mid term prospects
- Shares remain materially below historic EV/Sales ratings achieved when group was in a growth phase


- Announced material bolt-on acquisition and simultaneously downgraded full year margin expectations on revenue mix
- Market reacted poorly to the news which also saw cessation of share buy-back program. We continue to see significant value at these levels, as group rebuilds market trust from here

Equity markets valuations have recovered since March



UK Small companies seem to continue to offer attractive absolute and relative value

Aggregate Market Value (Discount)/Premium to Default Quest® fair value



Number of companies ¹	19,357	3,681	2,478	10,171	954	864	665
----------------------------------	--------	-------	-------	--------	-----	-----	-----

Market cap total	\$132trn	\$72trn	€13trn	\$35trn	£2.8trn	£329bn	£48bn
------------------	----------	---------	--------	---------	---------	--------	-------

Return on reversion to LT average	-7%	-15%	+6%	-7%	+9%	+52%	+77%
-----------------------------------	-----	------	-----	-----	-----	------	------


Source: Canaccord Quest® as at 6th October 2025 - 20 years to end December 2024. Odyssean Capital. ¹ Only includes UK quoted companies where there is at least one broker forecast. Mid values are implied. **Past performance is no guarantee of future performance** and the value of investments can go up and down

EV/Sales ratings for 7/top 10 portfolio companies

Excluding Elementis (largest investment and transformed since 2009)



Current portfolio top 10 (exc. SPI, BLN & ELM) - NAV weighted mean NTM EV/Sales




With some recovery since April months the portfolio EV/Sales ratio has only traded at a lower level than current 16% of the time since June 2006

Source: Factset Consensus estimates as at 6/10/25 and Odyssean analysis. Period 30th June 2006 to 3rd October 2025. Based on OIT portfolio and weightings as at end of September 2025 excluding Spire Healthcare (IPO 2014), Blackline (IPO 2007) and Elementis

Views and opinions of Odyssean Capital LLP. Past performance is no guarantee of future performance and the value of investments can go up and down. Capital at Risk


Themes across portfolio companies



Portfolio contains many businesses going through transformation




Transformations often exhibit an ‘s-curve’ profile – many names poised to accelerate?



High conviction portfolio



Top portfolio holdings¹



- NCC
- XPP
- Elementis
- Dialight
- Gooch
- Xaar
- Genus
- James Fisher
- Spire
- Blackline
- Other
- Cash


- Top 10 holdings account for 87% of NAV. Anticipate this will fall materially as catalysts in top holdings are delivered
- Further investments made into Dialight, Blackline, NCC and Essentra on share price weakness and available liquidity
- Two new toehold positions initiated in the period with scope to scale as diligence progresses
- Two small positions fully exited both driven by better opportunities identified elsewhere
- Net cash balance of c.1.3% at period end

Source: ¹ Odyssean Capital LLP, Link. As at 30th September 2025. Figures may not add up to 100% due to rounding


Past performance is no guarantee of future performance. Capital at risk.



Focused on our core sectors and core market cap range



- Industrials
- TMT
- Healthcare & Life Sciences
- Business Services
- Cash + Other



- Industrials remains the largest sector exposure
- Net cash balance of c1.3% - running fully invested, reflecting attractive opportunities we see in the market today


- 65% of invested exposure in core target market cap range of £100m-£1bn
- Exposure to positions out of sweet spot size range driven by market performance
- NAV weighted mean market cap of £470m and median market cap of £319m respectively
- Threshold to get into the FTSE 250 currently c.£570m²

Source: ¹Odyssean Capital LLP, Link. As at 30th September 2025. ²Deutsche Numis estimate as at 4th September 2025.

Figures may not add up to 100% due to rounding Capital at risk.

UK Smaller Companies can provide global exposure

OIT's portfolio is more international currently than the FTSE 100



- Portfolio revenue generation is balanced by geographic area, which we believe spreads political and economic risk
- Limited exposure from companies shipping goods into/out of the US – most production in region, for sale in region – “Local for Local”
- OIT's portfolio derives c.21% of revenues from the UK, less than the FTSE 100
 - UK exposure significantly driven by Spire which is currently in a sales process. Excluding Spire UK exposure c.16% of portfolio revenues
- We believe that many of the portfolio companies with significant overseas sales and earnings are undervalued compared with international peers

Source: ¹ Odyssean Capital and Link. As at 30th September 2025. ² FactSet company filings. ³Liberum/Bloomberg as at 30th June 2025. Odyssean strategy does not attempt to match any composition of any index including the FTSE Small Cap Index. Data is provided for information purposes only. Views and opinions of Odyssean Capital LLP. **Capital at risk.**

Special situations across the portfolio



Lots of ways for companies to create/unlock value

Holding	Margin improvement	Undervalued/hidden growth	SOTP ¹ discount	Material cost synergies for a trade buyer	Geographic arbitrage	Market share growth/recovery	Other
nccgroup	✓	✓	✓✓	✓	✓	✓	Scarcity value
XP XP Power	✓	✓✓		✓	✓	✓	Manufacturing footprint
ELEMENTIS	✓	✓		✓	✓	✓	Optimise St Louis plant
Dialight	✓✓	✓	✓	✓✓	✓	✓	Introduce automation
Gooch & Housego	✓	✓		✓✓	✓		Defence contract awards
Xaar	✓✓	✓✓		✓	✓	✓✓✓	New revenue areas/product
Genus	✓✓	✓✓	✓✓	✓	✓	✓	VAP3; further PRP approvals
James Fisher and Sons plc Pioneering Sustainably	✓✓	✓	✓	✓			Defence contract awards
Spire Healthcare	✓	✓	✓	✓✓			Strategic review outcome
blackline safety	✓✓	✓		✓✓		✓✓✓	Further ME contract wins

Note: Views and opinions of Odyssean Capital as at the date of this presentation. ¹SOTP – Sum of the Parts. Capital at risk.

Elementis case study

Specialty chemicals player, re-invigorated following management change



What is Elementis


- Vertically integrated specialty chemical player – owns unique mineral assets
- Products sold into coatings and personal care end markets. Products typically a small part of end customer product costs but have significant impact on performance

Why we are still invested

- Initially invested in 2020 at attractive valuation, backing a self-help story focused on improving margins and non-core disposals
- Significant progress made driven by active shareholder engagement – balance sheet de-geared, disposals made leaving 100% specialty chem focused group, material cost savings executed, board strengthened, and exec team changed
- New CEO appointed in 2025 -> set out clear ambitions for more self-help.
 - Enhanced medium to long term growth from a) +50% increase in R&D to drive NPD b) targeting incremental markets worth the same as existing markets
 - Addressing historic poor operational performance in St Louis – drag on sales and costs
 - Further \$10m cost savings, of which \$4m already delivered from procurement

How we believe we can still exceed our return hurdles for next 2-3 years

- “clean” investment story ex Talc and with revitalised management, story is attracting new and lapsed shareholders -> stock is quite under owned with mainstream UK investors. This should be supportive for the rating
- Volume recovery still to come – and very operationally geared. This, and self-help should drive above trend & exciting earnings growth for next 3 years



	Initial investment	FY 24	Target
% revenue 'specialty'	57%	82%	100%
EBIT %	14.1%	17.4%	23.0%+
Leverage	2.7x	1.0x	Sub 1.0x

Note: ‘Specialty’ revenue excludes talc and chromium businesses

‘Target’ refers to targets set out by new CEO at 2025 interim results

Outlook - update



We remain optimistic for the medium term; “climbing wall of worry”?

Overall market conditions

- Market sentiment appears to be improving – remarkable IPO market is showing signs of being open
- UK government finances remain stretched – further tax rises almost a certainty in October November
- Liquidity remains poor -> but more evidence this is starting to work in our favour

Opportunities & reasons to be positive


- UK equities remain undervalued in absolute and relative terms, especially UK Smaller Companies
- “Green shoots” of the “animal spirits” continuing
- Portfolio trading at low EV/sales multiples -> significant re-rating potential on top of sales growth
- Significant self-help opportunities and possible near-term catalysts in portfolio -> **we are becoming more confident of this**
- Tight liquidity has the potential to work in reverse as sentiment improves/fog of uncertainty clears. Also, M&A back?
- US exceptionalism on the wane

Risks & reasons to be cautious

- Slight US\$ drag short term
- Macro and political risks
 - Tariff induced slowdown /recession; mitigated by low inventory levels in supply chains
 - International investors concerned about fiscal competence in the France, UK & USA -> impact on gilt/treasury yields
 - Stagflation
 - Crowding out of private sector by public sector in UK – albeit limited impact on our portfolio

As at 30th September. Views and opinions of Odyssean Capital as at the date of this presentation.

Past performance is no guarantee of future performance and the value of investments can go up and down




Supporting Portfolio
& Market Data

Our investment strategy has delivered strong long-term returns


15-year track record across varied market conditions



Annualised return



Total cash-on-cash multiple




- **Performance net of all fees**
- **No use of derivatives**
- **No gearing**

Notes: Performance measured over time current strategy has been in the market, comprising period 01/07/09 until 06/02/17 during which Stuart Widdowson was lead manager of Strategic Equity Capital plc, and period 1/5/18 to 30/09/25 the period from IPO of OIT to the last week ending prior to compilation of these materials. Strategy returns shown are based on NAV total return per share performance and are net of all fees. Source: Link Asset Services, Bloomberg, Odyssean Capital, SEC. DNSC + AIM – Deutsche Numis Smaller Companies + AIM excluding investment companies Total Return Index

Capital at risk. Past performance is no guarantee of future performance and the value of investments can go up and down.

Investment Process

How we filter investment opportunities




Source: Odyssean Capital as at the date of the presentation.

Capital at risk. Past performance is no guarantee of future performance and the value of investments can go up and down.

The investment cycle

Looking for signs of improving fundamentals in UK Equities?



Source: Morgan Stanley Wealth Management.


Note: The percentages indicated above are hypothetical. **Hypothetical performance is not a guarantee of future performance** or a guarantee of achieving overall financial objectives²⁰

Portfolio sector exposure overtime

Industry exposure shifts driven by where we believe there are opportunities



Sectoral split over time



- Focus on our 4 core sectors – Industrials, TMT, Healthcare and Business Services
- Industrials remains the largest sector exposure

Portfolio company voting record over Q3 2025

Continued to follow our consistent guidelines and raise our concerns where appropriate




- Quiet period for meetings through summer months

Number of meetings	1
Number of resolutions	15
Number voted	15
Voted with management	13
Voted against management	2
Abstained	0

Investment strategy recap – neither growth nor value



Based on 3 pillars: Valuation, Quality and Engagement, with Sector focus



Valuation

- Invest at a significant discount to owner's valuation
- Look for businesses with multiple drivers of equity value growth (sales; margin; rating; free cashflow; M&A)
- "Make money", not beat an index

Quality

- Strict quality overlay to complement value focus
- "Good companies"
- Limit downside

Engagement

- Seek out "self-help" / transformation situations
- Integrated
- Proactive not reactive
- Tend to engage anyway as a Top 5 shareholder

- We aim to make money (target >15% IRR on every investment) with a favourable risk/reward
- Sector focus (TMT, Healthcare, Industrials, Services)

Sectors we focus on

We focus on four key sectors we know well



- We believe the best investment decisions are made from a base of knowledge and experience
- We focus on sectors where the team has expertise and where we have successfully made money
- Our core sector focus is driven by our investment approach
 - TMT: Software managed services and niche electronics
 - Services: Higher value-add “white collar” and tech enabled services
 - Healthcare: Services, not speculative pharma/biotech
 - Industrials: Niche, high IP products
- Companies with the following characteristics best suit our investment approach:
 - Low cyclicity
 - B2B focus
 - High/improving ROCE/cash margins
 - In-house sector expertise

Odyssean: view of main sectors

	Low cyclicity	B2B focus	High ROCE/cash margins	Sector expertise
TMT	●	●	●	●
Services	●	●	●	●
Healthcare	●	●	●	●
Industrials	○	●	○	●
Financials	○	○	●	○
Consumer	○	○	○	○
Property	○	○	○	○
Resources	○	○	○	○


Sectors we focus on

Corporate engagement

Goal to augment returns from stock selection



- We use engagement to create, defend or recover value and to deliver differentiated returns
- The investment team has more than 23 years' experience engaging with smaller quoted companies
- Team members are well networked and believe that persuasion with superior knowledge and understanding achieves the best results
- Peers are often open to supporting an engaged shareholder with change proposals
- Historic focus on Governance/financial performance
- Increasing focus on Environmental and Social disclosure and performance



Spectrum of our engagements



Level of engagement

- Exec meetings
- Proactive voting

- Chairman meeting
- Broker engagement
- Other shareholder discussions
- Exploration of ideas

- Chairman & NED meetings
- Writing formal letter to Board
- Specific shareholder proposals
- Voting co-operation

- Seek Board seat or change board members
- Propose resolutions at either AGM or call GM

Portfolio construction

Our strategy is more similar to Private Equity than other Public Equity funds



	Typical Long Only	Odyssean Strategy	Typical Private Equity
Number of positions	50-100	Up to 25	10-15
Typical position size	1%	3-8% at cost, max 20%	10%
Typical holding period	Variable	3-5 years	3-5 years
Due diligence	Light to Medium	Medium to High	High/Forensic
Typical target ownership	0.5-3%	2-20%	Majority/Supermajority
Sectors	Own most/All	Focus on a few	Focus on a few
Control	No control	Influencing stake	Full control
Approach to risk	Diversification & tracking error	Focus & due diligence	Focus & due diligence
Investment mindset	Outperform index	Absolute return	Absolute return
Engagement	Negligible	Medium/High	Medium/High
Typical cash balance	0-5%	5-10%	n/a

Odyssean Investment Trust - key company facts



NAV	£224m ¹
Shares in issue	133,944,212 ¹
Domicile	UK Full listing, London Stock Exchange
Board	Fully independent. Owns c.1% of issued share capital. Will use all fees, post tax, to buy shares
AIFM	Internally managed, small registered UK AIFM. Portfolio Management delegated to Odyssean Capital LLP
Discount control/realisation opportunity	Opportunity for shareholders to rollover or realise all of their investment at NAV less costs, every 7 th year post IPO (May 2018). First tender offer completed in June 2024 50% of profit from takeovers to be used to buy back shares if the average discount exceeds 5% for 60 days prior to exit
Gearing	No structural gearing envisaged. Ability to gear up to 10% for short term liquidity purposes. Net cash balances likely to be maintained to enable agile purchases of blocks of stock
Fees	Management fee lower of 1.0% of net assets/market capitalisation. Performance fee 10% of NAV TR outperformance vs (comparator index +1% p.a.) on a rolling three-year basis with a high watermark. 50% of performance fees paid in shares/used to buy shares if at a discount
Comparator index	Deutsche Numis Smaller Companies plus AIM ex Investment Companies index
Ticker	OIT
ISIN	GB00BFFK7H57

¹As at 30th September 2025. Capital at risk.

Further performance data

As at 30th September 2025



Performance	%		
	1 year	3 year	5 year
NAV Total Return Per Share ¹	-1.3%	+11.7%	+57.0%
Share price return ²	-7.9%	+5.0%	+58.3%
DNSC + AIM ex IC Total Return ²	+8.3%	+27.6%	+35.8%

Source: ¹Link Asset Services, Bloomberg, Odyssean Capital; Deutsche Numis Smaller Companies (“DNSC”) plus AIM ex Investment Companies Total Return Index. Rebased to start NAV ² Bloomberg. The DNSC + AIM ex Investment Company index is only used for the purposes of calculating performance fees. OIT does not attempt to match the composition of this index. The investment strategy is unconstrained and not benchmarked against any particular index.


Past performance is no guarantee of future performance and the value of investments can go up and down.

OIT shareholder base

As at 30th September 2025




Shareholder base by investor type



- Wealth Manager
- Connected Parties
- Retail Investors
- Institutions
- Endowment
- Portfolio Managers
- Board

Shareholders >3%



Source: ¹ Equiniti as at 30th September 2025, Odyssean Capital LLP. Figures may not add up to 100% due to rounding



Important Information

This financial promotion has been issued and approved by Odyssean Capital LLP (“Odyssean”) which is authorised and regulated in the United Kingdom by the Financial Conduct Authority (FRN:783925) and is the portfolio manager of Odyssean Investment Trust Plc (“OIT” or “the Company”). Odyssean will not regard any other person as its customer.

OIT is incorporated in England and Wales with registered number 11121934. Its ordinary shares are admitted to the closed-ended investment funds category of the Official List of the FCA and traded on the main market of the London Stock Exchange (“LSE”). OIT is a small registered UK Alternative Investment Fund Manager (“AIFM”).

OIT is suitable for investors seeking a fund that aims to deliver capital growth over a long-term investment horizon (at least 5 years), who are prepared to bear capital losses and have at least basic market knowledge and experience. Investors should understand the risks involved, including the risk of losing all capital invested. OIT may not be suitable for investors who are concerned about short-term volatility and performance, seeking a regular source of income or who may be investing for less than 5 years. The Company does not offer capital protection.

This marketing presentation is for information purposes only and does not constitute an offer or invitation to anyone to purchase or sale of any funds, securities or financial instruments. The information contained in this document is strictly confidential and is intended for the sole use of the intended recipient. It must not be distributed onward. This document is not intended to form (and should not therefore be relied upon as forming) the basis of any investment decision. Prospective investors are strongly recommended to seek their own independent financial, investment, tax, legal and other advice before making a decision to invest.

This document is solely for the use of (a) **“Professional Clients”** as defined in the Glossary to the UK Financial Conduct Authority Handbook, or (b) to whom it may otherwise lawfully be communicated. The content does not represent and is not intended to constitute advice of any nature nor an investment recommendation or opinion regarding the appropriateness or suitability of any investment or strategy and does not consider the particular circumstances specific to any individual recipient to whom this material has been sent. Persons who do not have professional experience in matters relating to investments must not rely on the contents of this document. If you are in any doubt as to the matters contained in this document, you should seek independent advice where necessary.

The distribution of this document and the availability of OIT are restricted. This document is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation, and it is the responsibility of any person or persons in possession of this document to inform themselves of, and to observe, all applicable laws and regulations of any relevant jurisdiction.



Important Information

No representation or warranty, either expressed or implied, is or will be made or given and no responsibility or liability is or will be accepted by Odyssean Capital LLP or by any of their respective directors, officers, employees, members, agents or advisers in relation to the accuracy or completeness of the information contained in this document or any other written or oral communications with the recipient. Any responsibility or liability for any such information is expressly disclaimed.

To the best of our knowledge all data included herein is accurate as of the date of this presentation, unless stated otherwise. Odyssean Capital LLP has no obligation to update or otherwise revise such data after this date.

Certain statements contained herein are forward-looking and/or based on current expectations, projections, and information currently available to Odyssean Capital LLP. While we believe we have a reasonable basis for our comments and we have confidence in our opinions, actual results may differ from those we anticipate. We cannot assure future results and disclaim any obligation to update or alter any forward-looking statements, whether as a result of new information, future events, or otherwise.

Capital at risk. Investments fluctuate in value and may fall as well as rise. Investors may not get back the value of their original investment and **past performance is not necessarily a guide to future performance.** Investors should also note that changes in rates of exchange may cause the value of investments to go up or down. OIT's investment strategy entails various risks, none of which are described herein. All such risks should be carefully considered by prospective investors before making any investment decision.

OIT does not attempt to match the composition of any index and focuses on a concentrated high conviction portfolio. The Deutsche Numis Smaller Companies (DNSC) index is only used for the purposes of calculating performance fees.

OIT is a small registered UK AIFM and so it is not subject to UK sustainable investment labelling and disclosure requirements. Whilst also out-of-scope of the anti-greenwashing rules, the Company will apply them. For more information on the UK sustainable investment labelling and disclosure requirements, please check the FCA webpage
<https://www.fca.org.uk/consumers/sustainable-investment-labels-greenwashing>

Case studies are selected for illustrative purposes only to illustrate investment strategy and are not investment recommendations.

Odyssean Capital LLP is a limited liability partnership incorporated in England under No OC417961. Authorised and regulated in the United Kingdom by the Financial Conduct Authority (FRN:783925). The list of members is held at the Registered Office: 6 Stratton Street, London, W1J 8LD.

Quest Disclaimer



Appendix: Important Disclosures

Quest® is at this stage registered in the UK and in the USA, and common law trademark rights are asserted in other jurisdictions.

For the purposes of UK regulation Canaccord Genuity Limited ("CGL") produces non-independent research which is a marketing communication under the Financial Conduct Authority (FCA) Conduct of Business Rules and an investment recommendation under the Market Abuse Regulation and is not prepared in accordance with legal requirements designed to promote the independence of investment research, nor is it subject to any prohibition on dealing ahead of the dissemination of investment research. However, Canaccord Genuity Limited does have procedures in place to identify and manage conflicts of interest which may arise in the production of non-independent research, which include preventing dealing ahead and Information Barrier procedures. For purposes of FINRA Rule 2241, this publication is considered third-party research. Further detail on Canaccord Genuity Limited's conflict management policies can be accessed at the following website (provided as a hyperlink if this report is being read electronically): <http://www.canaccordgenuity.com/en/cm/SiteInformation/Disclaimer/UK-Disclosures/>.

All share price data is as of close of business on the previous business day unless otherwise stated.

Analyst Certification

Each authoring Quest® analyst and/or sales person of Canaccord Genuity Limited whose name appears on the front page of this research hereby certifies that (i) the recommendations and opinions expressed in this research accurately reflect the author's personal, independent and objective views about any and all of the designated investments or relevant issuers discussed herein and (ii) the author's compensation was, is, or will be split into 2 elements: 1) a fixed base salary amount and 2) a variable discretionary bonus amount which is based on, amongst a number of factors, commission revenues generated by CGL. Such commission revenues include commissions received by CGL that were, are, or will be, directly or indirectly, related to the specific recommendations or views expressed by the author in this research or public appearance. Opinions and recommendations set forth in my Research Reports and/or Sales Notes may be influenced by such variable compensation.

Analysts and salespersons employed outside the US are not registered as research analysts with FINRA. These analysts may not be associated persons of Canaccord Genuity LLC and therefore may not be subject to FINRA Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Quest® Methodology

Quest® is an analytical tool that involves use of a set of proprietary quantitative algorithms and value calculations to derive a number of corporate performance and valuation metrics, including assigning a Default Quest® value per share and generating a triAngle Score, which is a relative ranking based on a number of operational and valuation metrics. These algorithms and value calculations are consistently applied to all the companies included in the Quest® database. Third-party data (including consensus earnings estimates) are systematically translated into a number of default variables and incorporated into the algorithms. The source financial statement, pricing, and earnings data provided by outside data vendors are subject to quality control and may also be adjusted to more closely measure the underlying economics of firm performance. These adjustments provide consistency when analyzing a single company across time, or analyzing multiple companies across industries or national borders. As the thirdparty data are updated, the triAngle Score generated by Quest®, and the Default Quest® value per share may change. The default variables may also be adjusted by the user to produce alternative values, any of which could occur. Additional information about the Quest® methodology is available on request.

Risks to Quest® Value Per Share

Quest® valuation uses a set of future assumptions to generate a discounted cash flow valuation for each company. These are based either on a combination of consensus forecasts, default Quest® algorithms and any adjustments which the author has made as defined within this note. The key risks to this scenario centre around whether the forecasts and assumptions used will be validated over time. This includes the effects of the macro economic environment, changes to political landscape in the company's markets and exchange rate fluctuations. Aside from this, the competitive landscape in the industry may change, influencing the company's ability to sustain its level of cash flow returns. The company's own execution of its strategy may also be influential. In addition, any unforeseen change in the company's strategic objectives to the extent that they change the company's assets, the financial structure of the company and the cash flow generated.

Quest® Distribution of Ratings (as of 28/01/2022)

Rating	Number of Recommendations	IB Clients
Buy	8	100%
Hold	0	0%
Sell	0	0%

Quest® Ratings System

Quest® Ratings are as of the date of the relevant publication only. Canaccord Genuity Limited does not undertake to update its Quest® recommendations or research within a specified timeframe.

BUY: We believe the stock to be undervalued on a net present value basis at the time of writing. This analysis can be based on the default Quest®-based DCF model; alternatively, it can be based on an adjusted DCF model or other valuation metrics.

HOLD: We believe the stock to be fairly valued on a net present value basis at the time of writing. This analysis can be based on the default Quest®-based DCF model; alternatively, it can be based on an adjusted DCF model or other valuation metrics.

SELL: We believe the stock to be overvalued on a net present value basis at the time of writing. This analysis can be based on the default Quest®-based DCF model; alternatively, it can be based on an adjusted DCF model or other valuation metrics.

Quest® 12-Month Recommendation History as of 28/01/2022

A list of all the recommendations on any issuer under coverage that was disseminated during the preceding 12-month period may be obtained at the following website <https://disclosuresquest-12MthHistory.canaccordgenuity.com/>.

Past Performance

In line with Article 44(4)(b), MiFID II Delegated Regulation, we disclose price performance for the preceding five years or the whole period for which the financial instrument has been offered or investment service provided where less than five years. Please note price history refers to actual past performance, and that past performance is not a reliable indicator of future price and/or performance.

Online Disclosures

For important information and company-specific Quest® disclosures please see Important Disclosures at the following website: <https://disclosuresquest.canaccordgenuity.com/>.

Compendium Report

This report covers six or more subject companies and therefore is a compendium report and CGL and its affiliated companies hereby direct the reader to the specific disclosures related to the subject companies discussed in this report, which may be obtained at the following website: <https://disclosuresquest.canaccordgenuity.com/> or by sending a request to Canaccord Genuity Corp. Research, Attn: Disclosures, P.O. Box 10337 Pacific Centre, 2200-609 Granville Street, Vancouver, BC, Canada V7Y 1H2; or by sending a request by email to disclosures@canaccordgenuity.com. The reader may also obtain a copy of Canaccord Genuity's policies and procedures regarding the dissemination of research by following the steps outlined above.

Short-Term Trade Ideas

Authoring Analysts may discuss "short-term trade ideas" in research reports. A short-term trade idea offers a near-term view on how a security may trade, based on market and trading events or catalysts, and the resulting trading opportunity that may be available. Separately, Canaccord Genuity may offer fundamental research on such securities. Any such trading strategies discussed in research reports are distinct from and do not affect the Canaccord Genuity research analysts' fundamental equity rating for such stocks. A short-term trade idea may differ from the price targets and recommendations in our published research reports that reflect the research analyst's views of the longer-term (i.e. one-year or greater) prospects of the subject company, as a result of the differing time horizons, methodologies and/or other factors. It is possible, for example, that a subject company's common equity that is considered a long-term 'Hold' or 'Sell' might present a short-term buying opportunity as a result of temporary selling pressure in the market or for other reasons described in the research report; conversely, a subject company's stock rated a long-term 'Buy' or 'Speculative Buy' could be considered susceptible to a downward price correction, or other factors may exist that lead the research analyst to suggest a sale over the short-term. Short-term trade ideas are not ratings, nor are they part of any ratings system, and the firm does not intend, and does not undertake any obligation, to maintain or update short-term trade ideas. Short-term trade ideas are not suitable for all investors and are not tailored to individual investor circumstances and

Quest Disclaimer



objectives, and investors should make their own independent decisions regarding any securities or strategies discussed herein. Please contact your salesperson for more information regarding Canaccord Genuity's research.

General Disclaimers

See "Required Company-Specific Disclosures" above for any of the following disclosures required as to companies referred to in this report: manager or co-manager roles; 1% or other ownership; compensation for certain services; types of client relationships; research analyst conflicts; managed/co-managed public offerings in prior periods; directorships; market making in equity securities and related derivatives. "Canaccord Genuity" is the business name used by certain wholly owned subsidiaries of Canaccord Genuity Group Inc., including Canaccord Genuity LLC, Canaccord Genuity Limited, Canaccord Genuity Corp., and Canaccord Genuity (Australia) Limited, an affiliated company that is 50% owned by Canaccord Genuity Group Inc.

The authors who are responsible for the preparation of this research are employed by Canaccord Genuity Limited, which is authorised and regulated by the Financial Conduct Authority.

The authors who are responsible for the preparation of this research have received (or will receive) compensation based upon (among other factors) the Investment Banking revenues and general profits of Canaccord Genuity. However, such authors have not received, and will not receive, compensation that is directly based upon or linked to one or more specific Investment Banking activities, or to recommendations contained in the research.

The information contained in this research has been compiled by Canaccord Genuity Limited from sources believed to be reliable, but (with the exception of the information about Canaccord Genuity) no representation or warranty, express or implied, is made by Canaccord Genuity Limited, its affiliated companies or any other person as to its fairness, accuracy, completeness or correctness. Canaccord Genuity has not independently verified the facts, assumptions, and estimates contained herein. All estimates, opinions and other information contained in this research constitute Canaccord Genuity Limited's judgement as of the date of this research, are subject to change without notice and are provided in good faith but without legal responsibility or liability.

From time to time, Canaccord Genuity's salespeople, traders, and other professionals provide oral or written market commentary or trading strategies to our clients and our proprietary trading desk that reflect opinions that are contrary to the opinions expressed in this research. Canaccord Genuity's affiliates, principal trading desk, and investing businesses also from time to time make investment decisions that are inconsistent with the recommendations or views expressed in this research.

This research is provided for information purposes only and does not constitute an offer or solicitation to buy or sell any designated investments discussed herein in any jurisdiction where such offer or solicitation would be prohibited. As a result, the designated investments discussed in this research may not be eligible for sale in some jurisdictions. This research is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. This material is prepared for general circulation to clients and does not have regard to the investment objectives, financial situation or particular needs of any particular person. Investors should obtain advice based on their own individual circumstances before making an investment decision. To the fullest extent permitted by law, none of Canaccord Genuity Limited, its affiliated companies or any other person accepts any liability whatsoever for any direct or consequential loss arising from or relating to any use of the information contained in this research.

For Canadian Residents:

This research has been approved by Canaccord Genuity Corp., which accepts sole responsibility for this research and its dissemination in Canada. Canaccord Genuity Corp. is registered and regulated by the Investment Industry Regulatory Organization of Canada (IIROC) and is a Member of the Canadian Investor Protection Fund. Canadian clients wishing to effect transactions in any designated investment discussed should do so through a qualified salesperson of Canaccord Genuity Corp. in their particular province or territory.

For United Kingdom and European Residents:

This research is for persons who are Eligible Counterparties or Professional Clients only and is exempt from the general restrictions in section 21 of the Financial Services and Markets Act 2000 (or any analogous legislation) on the communication of invitations or inducements to engage in investment activity on the grounds that it is being distributed in the United Kingdom only to persons of a kind described in Article 19(5) (Investment Professionals) and 49(2) (High Net Worth companies, unincorporated associations etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended). It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. This material is not for distribution in the United Kingdom or Europe to retail clients, as defined under the rules of the Financial Conduct Authority.

For United States Persons:

This research is distributed by Canaccord Genuity Limited in the United States to "major US institutional investors", as defined under Rule 15a-6 promulgated under the US Securities Exchange Act of 1934, as amended, and as interpreted by the staff of the US Securities and Exchange Commission (SEC). This research is also distributed in the United States to other institutional investors by Canaccord Genuity LLC, who accepts responsibility for this report and its dissemination in the United States. US clients wishing to effect transactions in any designated investment discussed should do so through a qualified salesperson of Canaccord Genuity LLC. Analysts employed outside the US, as specifically indicated elsewhere in this report, are not registered as research analysts with FINRA. These analysts may not be associated persons of Canaccord Genuity LLC and therefore may not be subject to FINRA Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

For Jersey, Guernsey and Isle of Man Residents:

This research is sent to you by Canaccord Genuity Wealth (International) Limited ("CGWI") for information purposes and is not to be construed as a solicitation or an offer to purchase or sell investments or related financial instruments. This research has been produced by an affiliate of CGWI for circulation to its institutional clients and also CGWI. Its contents have been approved by CGWI and we are providing it to you on the basis that we believe it to be of interest to you. This statement should be read in conjunction with your client agreement, CGWI's current terms of business and the other disclosures and disclaimers contained within this research. If you are in any doubt, you should consult your financial adviser.

CGWI is licensed and regulated by the Guernsey Financial Services Commission, the Jersey Financial Services Commission and the Isle of Man Financial Supervision Commission. CGWI is registered in Guernsey and is a wholly owned subsidiary of Canaccord Genuity Group Inc.

For Australian Residents:

This research is distributed in Australia by Canaccord Genuity Limited. Under ASIC Class Order (CO 03/1099), Canaccord Genuity Limited is exempt from the requirement to hold an Australian financial services licence for the provision of its financial services to you. Canaccord Genuity Limited is authorised and regulated by the Financial Conduct Authority under the laws of the United Kingdom which differ from Australian laws. This research is provided to you on the basis that you are a 'wholesale client' within the meaning of section 761G of the Corporations Act 2001 (Cth). To the extent that this research contains any advice, this is limited to general advice only. Recipients should take into account their own personal circumstances before making an investment decision. Clients wishing to effect any transactions in any financial products discussed in this report should do so through a qualified representative of Canaccord Genuity (Australia) Limited AFS Licence No 234666.

For Hong Kong Residents:

This research is distributed in Hong Kong by Canaccord Genuity (Hong Kong) Limited who is licensed by the Securities and Futures Commission. This research is only intended for persons who fall within the definition of professional investor as defined in the Securities and Futures Ordinance. It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. Recipients of this report can contact Canaccord Genuity (Hong Kong) Ltd. (Contact Tel: +852 3919 2561) in respect of any matters arising from, or in connection with, this research.

Additional information is available on request.

Copyright © Canaccord Genuity Corp. 2022. – Member IIROC/Canadian Investor Protection Fund

Copyright © Canaccord Genuity Limited 2022. – Member LSE, authorized and regulated by the Financial Conduct Authority.

Copyright © Canaccord Genuity LLC 2022. – Member FINRA/SIPC

Copyright © Canaccord Genuity (Australia) Limited 2022. – Participant of ASX Group, Chi-x Australia and of the NSX. Authorized and regulated by ASIC.

All rights reserved. All material presented in this document, unless specifically indicated otherwise, is under copyright to Canaccord Genuity Corp., Canaccord Genuity Limited, Canaccord Genuity LLC or Canaccord Genuity Group Inc. None of the material, nor its content, nor any copy of it, may be altered in any way, or transmitted to or distributed to any other party, without the prior express written permission of the entities listed above.

Accounts, Share Prices & Global Consensus Estimates data provided in conjunction with S&P Capital IQ © 2022; Benchmark Sector comparatives are based on the Global Industry Classification Standard (GICS®) and provided in conjunction with S&P Capital IQ © 2022 (and its affiliates, as applicable). Share prices are relative to the relevant regional benchmark MSCI Index. Please note that analyst data and Quest® data may differ due to different sources and calculation methods.

All rights reserved. Quest®, CITN®, Companies in the News™, CFROC® and triAngle™ are all trademarks of Canaccord Genuity Limited. E&OE. © Canaccord Genuity Limited.

None of the material, nor its content, nor any copy of it, may be altered in any way, reproduced, or distributed to any other party including by way of any form of social media, without the prior express written permission of the entities listed above.

Contact details



Portfolio Manager

Odyssean Capital LLP
6 Stratton Street
London
W1J 8LD

www.odysseancapital.com

Stuart Widdowson
Tel: +44 (0)7710 031620
Email: info@odysseancapital.com

Investor Relations Partner

Cadarn Capital Ltd
We Work, Moor Place
1 Fore St Ave
London
EC2Y 9DT

www.cadarncapital.com

David Harris
Tel: +44 (0) 20 7019 9042
Email: info@cadarncapital.com

Odyssean Capital LLP is incorporated as a limited liability partnership in England and Wales under Partnership No. OC417961 and is authorised and regulated in the United Kingdom by the Financial Conduct Authority

Registered Office: 6 Stratton Street, London, W1J 8LD